Processa CFO Makes Direct Purchase of PCSA Shares as Company Advances Clinical Trial Enrollment
Processa Pharmaceuticals Chief Financial Officer Russell Skibsted purchased 2,324 shares of the company on March 31, 2026, spending $5,891 at $2.535 per share. The trade was reported on a Form 4 and leaves Skibsted with direct ownership of those shares. The stock is trading at $2.60 with analysts setting a price target of $25, per InvestingPro data…